Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of EVEGYN Vaginal Ovule in Healthy Women
NCT05361369Phase 1Completed
- Sponsor
- Exeltis
- Start
- May 2022
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of EVEGYN A in vaginitis, bacterial vaginosis (BV) and candidal vulvovaginitis, sponsored by Exeltis. Primary endpoints: Area Under the Concentration-Time Curve From Time Zero to 72 Hours and Maximum Plasma Concentration. Started May 2022; status: completed.
02
Drugs
EVEGYN A
03
Conditions
vaginitisbacterial vaginosis (BV)candidal vulvovaginitis
Beyond the preview
Go deeper on NCT05361369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05361369.